BEVACIZUMAB FOR RECURRENT HIGH-GRADE GLIOMA (HGG): ANALYSIS OF MONOTHERAPY VERSUS COMBINATION WITH CHEMOTHERAPY FROM A CANADIAN RETROSPECTIVE CHART REVIEW

被引：0
|
作者：
Kavan, Petr [1 ]
Sahebjam, Solmaz [2 ]
Garoufalis, Evgenia [3 ]
Guiot, Marie-Christine [4 ]
Muanza, Thierry
Del Maestro, Rolando [5 ]
Petrecca, Kevin [5 ]
Sharma, Rajesh [3 ]
机构：
[1] McGill Univ, Royal Victoria Hosp, Ctr Hlth, Montreal, PQ H3A 1A1, Canada
[2] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[3] McGill Univ, Ctr Hlth, Montreal, PQ, Canada
[4] Montreal Neurol Hosp, Inst Neuropathol, Montreal, PQ, Canada
[5] McGill Univ, Ctr Hlth, Montreal Neurol Inst & Hosp, Montreal, PQ, Canada
来源：
NEURO-ONCOLOGY | 2012年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：76 / 76
页数：1
相关论文
共 50 条
  • [21] Bevacizumab reduces toxicity of reirradiation in recurrent high-grade glioma
    Fleischmann, Daniel Felix
    Jenn, Johanna
    Corradini, Stefanie
    Ruf, Viktoria
    Herms, Jochen
    Forbrig, Robert
    Unterrainer, Marcus
    Thon, Niklas
    Kreth, Friedrich Wilhelm
    Belka, Claus
    Niyazi, Maximilian
    RADIOTHERAPY AND ONCOLOGY, 2019, 138 : 99 - 105
  • [22] CARBOPLATIN CHEMOTHERAPY IN PATIENTS WITH RECURRENT HIGH-GRADE GLIOMA
    Kaloshi, G.
    Rroji, A.
    Petrela, M.
    EUROPEAN JOURNAL OF NEUROLOGY, 2011, 18 : 605 - 605
  • [23] Carboplatin Chemotherapy in Patients With Recurrent High-grade Glioma
    Kaloshi, G.
    Rroji, A.
    Bushati, T.
    Petrela, M.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S588 - S588
  • [24] Carboplatin Chemotherapy in Patients with Recurrent High-grade Glioma
    Kaloshi, G.
    Petrela, M.
    CLINICAL ONCOLOGY, 2011, 23 (07) : 495 - 495
  • [25] Carboplatin Chemotherapy in Patients with Recurrent High-grade Glioma
    Murray, L. J.
    Bridgewater, C. H.
    Levy, D.
    CLINICAL ONCOLOGY, 2011, 23 (01) : 55 - 61
  • [26] RESULTS OF TREATMENT PEDIATRIC RECURRENT HIGH GRADE GLIOM (HGG) WITH COMBINATION OF BEVACIZUMAB AND IRINOTECAN
    Geludkova, O. G.
    Borodina, I. D.
    Melikian, A. G.
    Kushel, Y. V.
    Gorbatih, S. V.
    Pavlova, E. V.
    Kupzova, E. V.
    Kumirova, E. V.
    Mushinskaya, M. V.
    Shammasov, R. Z.
    Inyushkina, E. V.
    Boyarchuk, N. G.
    Salnikova, E. A.
    Maksimova, N. V.
    Shishkina, L. V.
    Ozerova, V. I.
    NEURO-ONCOLOGY, 2010, 12 : 53 - 53
  • [27] Anlotinib alone or in combination with temozolomide in recurrent high-grade glioma: A retrospective study.
    Yang, Qun-ying
    Guo, Cheng-Cheng
    He, Zhenqiang
    Lin, Fuhua
    Zhang, Ji
    Guo, Xiaoyu
    Chen, Yinsheng
    Jiang, Xiaobing
    Ke, Chao
    Chen, Zhongping
    Mou, Yonggao
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [28] ENCOURAGING OVERALL SURVIVAL (OS) WITH BEVACIZUMAB (BEV) IN PATIENTS WITH RECURRENT HIGH-GRADE GLIOMA (HGG) TREATED OUTSIDE CLINICAL TRIALS
    Hofer, S.
    Elandt, K.
    Greil, R.
    Hottinger, A. F.
    Lemke, D.
    Marosi, C.
    Pichler, J.
    Weder, P.
    Wick, W.
    Weller, M.
    ANNALS OF ONCOLOGY, 2010, 21 : 329 - 329
  • [29] Phase II study of sunitinib and irinotecan in patients with recurrent high-grade glioma (HGG).
    Grisanti, S.
    Pedersini, R.
    Ferrari, V. D.
    Liserre, R.
    Consoli, F.
    Poliani, L.
    Boglione, M.
    Rangoni, G.
    Montini, E.
    Simoncini, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [30] Concomitant Temozolomide plus radiotherapy for high-grade and recurrent meningioma: a retrospective chart review
    Katherine Belanger
    Timothy H. Ung
    Denise Damek
    Kevin O. Lillehei
    D. Ryan Ormond
    BMC Cancer, 22
12345